The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine detailed the ongoing questions about assessing the gaps in breastfeeding between women with, and without, epilepsy.
The Headaterm TENS device was shown to decrease pain at an 11.8% better rate than many acute migraine medications used in the emergency department in randomized trials, with data suggesting it is both effective and fast-acting.
The novel oxybate agent has been submitted as an investigational treatment for cataplexy and excessive daytime sleepiness in those ages 7 years and older with narcolepsy.
The drug proved effective in extending total sleep time over a 4-week study period, with minimal adverse events observed.
The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the findings of the MONEAD study and their implications for women with epilepsy.
The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital shared his insight into the potential of using an SCN1A-targeted adeno-associated viral vector-based gene therapy in epilepsy.
Findings from the small-scale study showed that the drug had target engagement with β-glucocerebrosidase as well as cerebrospinal fluid penetration.
The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the need for consistency in the messaging conveyed to women with epilepsy who are having children.
Those who have strokes with favorable imaging profiles have a higher likelihood of receiving endovascular thrombectomy as well as achieving high functional independence rates after 90 days.
Findings from a large scale analysis show higher rates of cognitive impairment and neuropsychiatric disturbances in patients with parkinsonism-dominant motor-manifest individuals.
Danielle B. Cross, MD, MS, a neurology resident in training, shares her thoughts on the importance of humility in medicine.
As was the case for siponimod’s FDA approval in March 2019, this regulatory decision by the European Commission for the selective sphingosine-1-phosphate receptor modulator was based on the phase 3 EXPAND trial.
The professor of neurology and epilepsy specialist at the Cleveland Clinic Lerner College of Medicine explains the decision-making process surrounding epilepsy surgery.
Use of rimabotulinumtoxinB (Myobloc; US WorldMeds) result in statistically significant reductions in sialorrhea compared to placebo with both 2500 U and 3500 U doses.
Neurology News Network for the week ending January 18, 2020.
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 17, 2020.
Lara Jehi, MD, professor of neurology and an epilepsy specialist at the Cleveland Clinic Lerner College of Medicine, detailed the process and decisions that patients with epilepsy face when considering surgery.
The assistant professor of neurology at the University of Wisconsin detailed the importance of transition clinics for pediatric patients with epilepsy.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Donald Frei, MD.
Donald Frei, MD, a neurointerventional surgeon in Colorado, recently appealed to the National EMS Advisory Council for improved EMS triage and transport protocols.
Findings from a large scale study of multiple sclerosis treatments showed greater levels of relapse resolution with oral corticosteroids and repository corticotropin injections compared to other treatments.
After first-step data suggested that one small molecule CGRP receptor antagonist and a monoclonal antibody against CGRP were successful and safe together in migraine. One of the study authors, Kathleen Mullin, MD, discussed the data.
New data from a report on US Medicaid program spending suggests that spending on disease-modifying therapies has more than doubled over a recent 7-year stretch, with no expected help from generic competition coming soon.
The FDA approved an updated drug label for the multiple sclerosis drug, including updates on immunizations and risks in specific patient populations.
Lara Jehi, MD, professor of neurology and an epilepsy specialist at the Cleveland Clinic Lerner College of Medicine, spoke to her work on individualized risk assessments for epilepsy surgery candidates and the impact it can have for both physicians and patients alike.
Biohaven’s small molecule CGRP receptor antagonist rimegepant has displayed safety and efficacy in a small cohort of patients with migraine using it alongside erenumab.
The neurostimulation device may help to accelerate the removal of a patient’s breathing tube by restoring neurological swallowing control.
Results of the 311 study of parampanel showed improvements in response/ seizure frequency regardless of age or concomitant enzyme-inducing anti-seizure drug use.
In a review of 5 clinical trials, non‐vitamin‐K oral anticoagulants were shown to be associated with a lower risk of fatal and disabling, as well as non-disabling, stroke compared to warfarin.
The recalled lot of lamotrigine used to treat epilepsy and bipolar disorder is set to expire in June 2021 and was distributed between August 23 and August 30, 2019.
